No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VERX240816P17500
- 0.88
- 0.000.00%
15min DelayTrading Jan 29 09:53 ET
0.00High0.00Low
0.00Open0.88Pre Close0 Volume5 Open Interest17.50Strike Price0.00Turnover245.85%IV56.70%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.88Extrinsic Value100Contract SizeAmericanOptions Type-0.0618Delta0.0049Gamma43.61Leverage Ratio-0.0591Theta-0.0020Rho-2.70Eff Leverage0.0123Vega
Intraday
- 5D
- Daily
News
Vertex Ventures announces allotment and issuance of new redeemable preference shares to fund future investments
637,000 US$ Class A RPS and 100,000 S$ Class A RPS has been announced for US$100 and $100 respectively per share.
Goldman Lists Its Top 25 Tactical Trades for Earnings Season
Vertex to Announce Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
Vertex Is Maintained at Neutral by Citigroup
Vertex Is Maintained at Neutral by Citigroup
Express News | Citigroup Maintains Neutral on Vertex, Raises Price Target to $36
Citi Maintains Vertex(VERX.US) With Hold Rating, Raises Target Price to $36
Citi analyst Steve Enders maintains $Vertex(VERX.US)$ with a hold rating, and adjusts the target price from $32 to $36.According to TipRanks data, the analyst has a success rate of 46.5% and a total a
Comments
Explore these stocks poised to benefit from innovations in biotech:
AstraZeneca: AstraZeneca is a leading biopharmaceutical company focused on developing innovative medicines, especially for rare diseases and metabolic disorders.
Novartis: Novartis is a global healthcare company pioneering innovative medical solutions, especially tackling rare genetic diseases through cutting-edge research and development.
Amgen: With a strong focus on rare diseases and oncology, Amgen ai...
AstraZeneca: AstraZeneca is a leading biopharmaceutical company focused on developing innovative medicines, especially for rare diseases and metabolic disorders.
Novartis: Novartis is a global healthcare company pioneering innovative medical solutions, especially tackling rare genetic diseases through cutting-edge research and development.
Amgen: With a strong focus on rare diseases and oncology, Amgen ai...
$Vertex(VERX.US$ they buy with huge mony any news!!?
Vertex's leadership is excited about the acquisition of TriLogix, expecting it to enhance their commitment to providing top-notch construction project control services.
1
Analysts predict Vertex to breakeven in less than a year, with an estimated yearly growth rate of 123%. If this rate is too optimistic, profitability may be delayed. The company's low debt reduces investment risk in the loss-making company.
Analysts believe that if approved, VX-548 could generate over $5B in annual sales for Vertex. Despite the trials not showing superiority over opioids, the safety and addiction advantage of the drug is seen as a significant benefit.
Read more